

Brad S Kahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7400633/publications.pdf>

Version: 2024-02-01

166
papers

10,469
citations

87888

38
h-index

34986

98
g-index

169
all docs

169
docs citations

169
times ranked

10059
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	27.0	1,532
2	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	27.0	1,449
3	PI3K γ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	27.0	956
4	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 826-833.	1.6	596
5	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
6	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. <i>Blood</i> , 2014, 123, 2944-2952.	1.4	505
7	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	1.4	349
8	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. <i>Journal of Clinical Oncology</i> , 2019, 37, 1790-1799.	1.6	266
9	Bendamustine is effective therapy in patients with rituximabâ€‘refractory, indolent Bâ€‘cell nonâ€‘Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 106-114.	4.1	217
10	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 790-800.	10.7	211
11	Duvelisib, a novel oral dual inhibitor of PI3K-Î³, is clinically active in advanced hematologic malignancies. <i>Blood</i> , 2018, 131, 877-887.	1.4	199
12	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 984-991.	1.6	183
13	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	1.4	167
14	Rituximab Extended Schedule or Re-Treatment Trial for Lowâ€‘Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. <i>Journal of Clinical Oncology</i> , 2014, 32, 3096-3102.	1.6	159
15	Follicular lymphoma: evolving therapeutic strategies. <i>Blood</i> , 2016, 127, 2055-2063.	1.4	142
16	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020, 136, 2308-2318.	1.4	133
17	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. <i>Haematologica</i> , 2019, 104, e211-e214.	3.5	122
18	Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three openâ€‘label studies. <i>British Journal of Haematology</i> , 2017, 179, 430-438.	2.5	116

#	ARTICLE	IF	CITATIONS
19	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 2634-2645.	1.4	111
20	The role of autologous stem cell transplantation in patients with nodal peripheral Tâ€cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019, 125, 1507-1517.	4.1	106
21	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	1.6	97
22	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.	1.6	93
23	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	1.4	90
24	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2020, 7, e660-e670.	4.6	86
25	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolbenzodiazepine-Based Antibodyâ€Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6986-6994.	7.0	77
26	Positron Emission Tomographyâ€Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
27	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel â€an update. <i>Leukemia and Lymphoma</i> , 2016, 57, 766-782.	1.3	70
28	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. <i>Haematologica</i> , 2017, 102, e156-e159.	3.5	68
29	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	1.4	62
30	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	3.5	62
31	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	1.6	60
32	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	6.3	56
33	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	4.1	51
34	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
35	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	4.1	47
36	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 3850-3852.	5.2	46

#	ARTICLE	IF	CITATIONS
37	Duvelisib (IPI-145), a PI3K-Î³ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3334-3334.	1.4	46
38	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1543-1551.	2.0	42
39	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	4.1	41
40	Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 359-364.	2.5	40
41	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	5.2	40
42	Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015, 33, 740-748.	1.6	36
43	Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. <i>British Journal of Haematology</i> , 2016, 173, 867-875.	2.5	36
44	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	1.4	35
45	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	1.6	33
46	Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2008, 45, 90-94.	3.4	32
47	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw249.	6.3	31
48	T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw248.	6.3	28
49	Targeting BCL-2 in Hematologic Malignancies. <i>Targeted Oncology</i> , 2018, 13, 257-267.	3.6	27
50	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	2.5	27
51	Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. <i>Acta Haematologica</i> , 2020, 143, 40-50.	1.4	27
52	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	7.0	26
53	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020, 34, 522-532.	7.2	26
54	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 3339-3350.	7.0	26

#	ARTICLE	IF	CITATIONS
55	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014, 154, 37-46.	3.2	25
56	Recommendations for Clinical Trial Development in Follicular Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw255.	6.3	23
57	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	1.4	23
58	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	1.6	23
59	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	1.4	22
60	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
61	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21
62	Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. <i>HemaSphere</i> , 2022, 6, e712.	2.7	21
63	Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. <i>Blood</i> , 2019, 134, 1538-1538.	1.4	20
64	Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-Î³, In Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 677-677.	1.4	20
65	Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. , 2019, 7, 70.		19
66	The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e335-e339.	0.4	19
67	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 675.	4.8	18
68	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	5.2	18
69	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	4.1	18
70	Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2019, 134, 751-751.	1.4	18
71	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012, 120, 304-304.	1.4	18
72	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17

#	ARTICLE	IF	CITATIONS
73	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 512-525.	3.8	16
74	Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematology, the, 2021, 8, e891-e901.	4.6	15
75	Follicular lymphoma: are we ready for a risk-adapted approach?. Hematology American Society of Hematology Education Program, 2017, 2017, 358-364.	2.5	14
76	Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 35-37.	1.4	14
77	VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e61-e67.	0.4	13
78	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). Blood, 2018, 132, 679-679.	1.4	13
79	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. Blood, 2019, 134, 349-349.	1.4	13
80	Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial. Blood, 2019, 134, 126-126.	1.4	12
81	VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network. Blood, 2008, 112, 265-265.	1.4	12
82	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances, 2022, 6, 2035-2044.	5.2	12
83	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw263.	6.3	10
84	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer Journal, 2018, 8, 27.	6.2	10
85	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. Blood, 2019, 134, 1525-1525.	1.4	10
86	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 753-753.	1.4	9
87	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). Blood, 2019, 134, 69-69.	1.4	9
88	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. Blood, 2020, 136, 27-28.	1.4	9
89	The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 â€” A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.. Blood, 2009, 114, 1661-1661.	1.4	9
90	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of Clinical Oncology, 2023, 41, 336-342.	1.6	9

#	ARTICLE	IF	CITATIONS
91	Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival. <i>Blood</i> , 2018, 132, 4146-4146.	1.4	8
92	ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≥65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL). <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7572-TPS7572.	1.6	7
93	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	1.2	7
94	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 757-757.	1.4	7
95	Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2019, 134, 1535-1535.	1.4	7
96	Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 4-6.	1.4	7
97	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. <i>Blood</i> , 2018, 132, 929-929.	1.4	6
98	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , 2018, 132, 1702-1702.	1.4	6
99	Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 213-217.	2.3	5
100	Emerging Therapy for the Treatment of Mantle Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1311-1318.	4.9	5
101	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	1.4	5
102	Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma: A Pooled Analysis. <i>Blood</i> , 2009, 114, 2681-2681.	1.4	5
103	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	1.4	5
104	Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 7505-7505.	1.6	5
105	Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood Advances</i> , 2021, , .	5.2	5
106	Bulky Aggressive B-Cell Lymphoma: To Radiate or Not to Radiate? That Is the Question. <i>Journal of Clinical Oncology</i> , 2014, 32, 1097-1098.	1.6	4
107	Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study. <i>Blood</i> , 2019, 134, 5243-5243.	1.4	4
108	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	1.4	4

#	ARTICLE	IF	CITATIONS
109	Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 2958-2958.	1.4	4
110	Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2020, 136, 3-4.	1.4	4
111	Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 433-8.	2.5	4
112	NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. <i>Blood Cancer Journal</i> , 2017, 7, 632.	6.2	3
113	Treatment With The Potent PI3K- γ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 1633-1633.	1.4	3
114	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	1.4	3
115	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	5.2	3
116	Current treatment approaches in follicular lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 740-3.	0.3	3
117	Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 732-734.	0.3	3
118	General Biomarker Recommendations for Lymphoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw250.	6.3	2
119	Long-term safety experience with bendamustine for injection in a real-world setting. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 647-650.	2.4	2
120	Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 861-870.	2.2	2
121	Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 663-672.	2.2	2
122	Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7546-7546.	1.6	2
123	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. <i>Blood</i> , 2018, 132, 2927-2927.	1.4	2
124	A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 32-34.	1.4	2
125	Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study. <i>Blood</i> , 2016, 128, 149-149.	1.4	2
126	Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial. <i>Blood</i> , 2021, 138, 3575-3575.	1.4	2

#	ARTICLE	IF	CITATIONS
127	Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. Clinical Advances in Hematology and Oncology, 2010, 8, 1-16.	0.3	2
128	An iatrogenic orphan?. Blood, 2019, 134, 1273-1274.	1.4	1
129	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	1.3	1
130	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole Continuation (BIONIC) Study. Blood, 2018, 132, 1615-1615.	1.4	1
131	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. Blood, 2018, 132, 453-453.	1.4	1
132	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). Blood, 2018, 132, 623-623.	1.4	1
133	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 3483-3483.	1.4	1
134	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. Journal of Clinical Oncology, 2018, 36, 10042-10042.	1.6	1
135	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 4758-4758.	1.4	1
136	RIP FCR?. , 2019, 16, .		1
137	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. Blood, 2019, 134, 1550-1550.	1.4	1
138	Recent Advances in Antibody-Drug Conjugates for Lymphoma. Oncology, 2020, 34, 522-534.	0.5	1
139	Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma. Blood, 2020, 136, 24-25.	1.4	1
140	COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience. Leukemia and Lymphoma, 2022, 63, 1723-1727.	1.3	1
141	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Advances, 2022, 6, 4736-4739.	5.2	1
142	BV for HL: can the responses last?. Blood, 2016, 128, 1540-1541.	1.4	0
143	Indolent lymphomas. Best Practice and Research in Clinical Haematology, 2018, 31, 1.	1.7	0
144	Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 65-67.	0.4	0

#	ARTICLE	IF	CITATIONS
145	Expression of the Bcl-2 Family of Regulatory Proteins by Quantitative Immunohistochemistry (AQUA) in Follicular Lymphoma.. Blood, 2009, 114, 4996-4996.	1.4	0
146	Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma. Blood, 2012, 120, 235-235.	1.4	0
147	Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting. Blood, 2016, 128, 5591-5591.	1.4	0
148	ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.. Journal of Clinical Oncology, 2018, 36, TPS7587-TPS7587.	1.6	0
149	Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.. Journal of Clinical Oncology, 2018, 36, 7538-7538.	1.6	0
150	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. Blood, 2018, 132, 2878-2878.	1.4	0
151	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	1.4	0
152	Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1593-1593.	1.4	0
153	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. Blood, 2018, 132, 4157-4157.	1.4	0
154	Can We Use MRD Status to Personalize Therapy in Mantle Cell Lymphoma?. , 2019, 16, .		0
155	Is It Time for Time-limited Therapy in Frontline CLL?. , 2019, 16, .		0
156	Keeping Your ESCHELONS Straight. , 2019, 16, .		0
157	Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?. , 2019, 16, .		0
158	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. Blood, 2019, 134, 5891-5891.	1.4	0
159	A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404. Blood, 2019, 134, 1541-1541.	1.4	0
160	Frontline CLL Options: An Embarrassment of Riches?. , 2020, 17, .		0
161	Picking a Partner: As in Life, it Matters for MYC. , 2020, 17, .		0
162	Are We Capable of Curing Follicular Lymphoma, But Just Afraid to Say It?. , 2020, 17, .		0

#	ARTICLE	IF	CITATIONS
163	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. Blood, 2020, 136, 15-16.	1.4	0
164	Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. Blood, 2020, 136, 50-50.	1.4	0
165	Two new indications for rituximab. Clinical Advances in Hematology and Oncology, 2006, 4, 901, 934.	0.3	0
166	Highlights in mantle cell lymphoma from the 2020 American Society of Clinical Oncology Annual Meeting: commentary. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 11, 14-17.	0.3	0